A5075689224- Gastric Cancer Management and Outcomes
- Sarcoma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Neuroblastoma Research and Treatments
- Metastasis and carcinoma case studies
- Neuroendocrine Tumor Research Advances
- Gastrointestinal Tumor Research and Treatment
- Genetic factors in colorectal cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Viral-associated cancers and disorders
- Pancreatic and Hepatic Oncology Research
- Bone Tumor Diagnosis and Treatments
- Colorectal Cancer Surgical Treatments
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Advanced Breast Cancer Therapies
- Lymphoma Diagnosis and Treatment
- Oral and Maxillofacial Pathology
- Tumors and Oncological Cases
- Cancer Immunotherapy and Biomarkers
- Neurofibromatosis and Schwannoma Cases
- Breast Cancer Treatment Studies
- Vascular Tumors and Angiosarcomas
Instituto Nacional de Enfermedades Neoplásicas
2012-2025
LBA246 Background: FLOT was established as a perioperative therapy for GC/GEJC following the Phase 2/3 FLOT4 study conducted in Germany, with pCR rate of 16% (Al-Batran et al, Lancet Oncol 2016). The global MATTERHORN (NCT04592913) showed statistically significant improvement D + vs placebo (P) at first interim analysis (Janjigian ESMO Congress 2023). Subgroup analyses by region and country were completed to assess rates benefit across population. Methods: Participants (pts) resectable...
279 Background: Colorectal cancer (CRC) represents the third cause of malignant neoplasm in world and second terms mortality. CRC is a major cancer-related morbidity mortality Peru. Diagnosis at younger ages challenge. In this study, we evaluated prognostic factors patients who were metastatic diagnosis or progressed to disease during follow-up. Methods: A descriptive cross-sectional between 2013 2022, 66 under 40 years old stage IV analyzed. Parameters age, gender, comorbidity, performance...
e14043 Background: Schwannomas are nerve sheath tumors that originate in Schwann cells. They usually solitary and sporadic manifest on peripheral, spinal or cranial nerves. It is the most common type of benign peripheral tumor adults. These represent a diagnostic challenge due to their rarity difficult differential diagnosis. Our objective was determine clinical pathological characteristics, as well therapeutic management patients with Schwannoma admitted our institution over period time....
The COVID-19 outbreak has resulted in collision between patients infected with SARS-CoV-2 and those cancer on different fronts. Patients have been impacted by deferral, modification, even cessation of therapy. Adaptive measures to minimize hospital exposure, following the precautionary principle, proposed for care during era. We present here a consensus prioritizing recommendations across continuum sarcoma patient care.A total 125 were soft-tissue, bone, visceral care. Recommendations...
Kaposi's sarcoma (KS) is a multifocal angioproliferative disease. In Peru, the implementation of highly active antiretroviral treatment (HAART) program was in 2005, model for treating patients with HIV-positive KS shifted to potential cure. this study, we aim compare clinicopathological characteristics and prognostic factors associated outcomes KS.We developed retrospective cohort study that includes HIV/AIDS seen Instituto Nacional de Enfermedades Neoplasicas between 1987 2017. Patients...
524 Background: Hepatocellular carcinoma (HC) is the most common primary tumor of liver and a significant health problem worldwide with check-point inhibitors oral multikinase (TKI) as first-line therapy for advanced diseases. While chemotherapy treatment may not be standardized in current clinical management guidelines, it remains only available option numerous Latin American countries. Methods: A retrospective review was carried out, patients older than 18 years, between January 2011...
345 Background: First-line (1L) treatment of GEJC and EAC is similar to that for gastric adenocarcinomas, based on evidence from 2 large phase 3 esophageal cancer trials. The KEYNOTE-590 trial (NCT03189719) showed 1L pembro + chemo significantly improved OS PFS in pts with cancer. KEYNOTE-859 (NCT03675737) OS, PFS, ORR HER2-negative or GEJC. This post hoc, exploratory analysis was conducted examine the efficacy subgroups GEJ subgroup KEYNOTE-859. Methods: Pts untreated advanced Siewert type...
Ewing's Sarcoma (ES) belongs to a group of rare and aggressive tumors, 30% have metastases at the onset; average age patients is between 10 20 years. This study aimed assess clinical-pathological characteristics, presentation, treatment modalities for local control, as well associated adverse events. An observational, descriptive, cross-sectional, retrospective was conducted, including over 14 years old diagnosed with 2010 2022 Instituto Nacional de Enfermedades Neoplásicas Lima-Peru. The...
e23557 Background: The management of soft tissue sarcomas (STS) presents a challenge in Peru, with fragmented health system and few centers specialized sarcoma care. There is no national cancer registry, which does not allow us to have real view the most prevalent types. Our aim was determine incidence Instituto Nacional de Enfermedades Neoplásicas (INEN) know care capacity nationwide. Methods: A retrospective study carried out INEN between 2009 2015 STS. Also, survey diagnosis treatment...
Abstract Background FLOT was established as a perioperative therapy for GC/GEJC following the Phase 2/3 FLOT4 study conducted in Germany, with pCR rate of 16% (Al-Batran et al, Lancet Oncol 2016). The global MATTERHORN (NCT04592913) showed statistically significant improvement D+FLOT vs placebo (P) + at first interim analysis (Janjigian ESMO Congress 2023). Subgroup analyses by region and country were completed to assess rates benefit across population. Methods Participants (pts) resectable...
Numerous studies have indicated that the temozolomide and capecitabine regimen (TEMCAP) exhibits a certain level of efficacy in treating advanced, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET). However, published data from Peru are limited. We hypothesize this could be viable therapeutic option for advanced GEP-NET Peruvian population.
Giant cell bone tumors (GCT) are primary locally aggressive neoplasms that occasionally manifest with distant metastasis. Denosumab, a fully humanized monoclonal antibody against the RANK ligand, is indicated for its effectiveness in treatment of unresectable or metastatic GCT. An observational, descriptive, cross-sectional, and retrospective study was conducted at Instituto Nacional de Enfermedades Neoplásicas Lima, Peru evaluating patients diagnosed between 2018 2022 who received...
Osteosarcoma is a primary bone tumor characterized by being chemosensitive. MAP the standard treatment which has been widely used in Instituto Nacional de Enfermedades Neoplasicas (INEN). In this abstract, we focus on evaluating prognostic factors and outcomes neoadjuvant at INEN. We conducted retrospective analysis of all non-metastatic osteosarcoma patients seen INEN Lima-Peru between November 2014 to February 2023. report with following criteria: (1) typical histological radiological...